<DOC>
	<DOCNO>NCT01086527</DOCNO>
	<brief_summary>Leukotriene receptor antagonist ( LTRAs ) frequently prescribe reduce symptom associate asthma . Singulair ( montelukast ) , manufacture Merck , popular LTRA , however effectiveness varies greatly individual . We interested understanding effectiveness Singulair vary greatly . For oral drug Singulair effective , body must efficiently absorb . We find blood level Singulair vary greatly individual , think variability responsible variability response . Drug absorption occur primarily intestine . Due difference chemical property drug , drug absorb easily drug require help special protein produce cell line intestine . These protein , transporter act like revolve door allow drug move intestine bloodstream . The activity transporter influence individual genetic variability . We think adsorption Singulair require help transport protein call OATP2B1 . We find single common genetic change protein associate low plasma concentration montelukast . In proposal determine plasma level montelukast individual two copy genetic change . We predict individual roughly half plasma level montelukast individual copy genetic change . Eventually , learn work allow doctor quickly test individual asthma determine well absorb Singulair possibly LTRAs . Knowing allow doctor adjust drug treatment individual basis maximize benefit treatment asthma .</brief_summary>
	<brief_title>Genotype Stratified Pharmacokinetic Study Montelukast</brief_title>
	<detailed_description>We previously report montelukast substrate transport OATP2B1 common variant SLCO2B1 ( gene cod OATP2B1 ) , c. [ 935G &gt; A ] , result substitution Argâ†’Glu amino acid position 312 , associate steady-state plasma concentration montelukast response ( 1 ) . Compared G/G homozygote , A/G heterozygotes low plasma concentration 1 6 month therapy . Additionally , score Asthma Symptom Utility Index high ( well asthma control ) G/G homozygotes compare A/G heterozygotes sample interval , prior treatment . We conclude genotype c.935 may contribute variability response montelukast . We recently complete study influence genotype c.935 co-ingestion citrus juice pharmacokinetics single 10-mg dose montelukast 26 adolescent subject physician-diagnosed asthma ( NCT00513760 ) . Twenty-one participant genotyped G/G homozygote five A/G heterozygote . The area montelukast plasma concentration vs. time curve ( AUC ) A/G heterozygotes 46 % low AUC G/G homozygotes , replicate early finding genotype c.935 influence pharmacokinetics montelukast . Assuming additive genetic model , data predict AUC montelukast individual carry A/A genotype would even lower heterozygote . The prevalence homozygous mutant allele ( A/A ) low among African European Americans ( 0 - 3 % ; http : //www.ncbi.nlm.nih.gov/projects/SNP/ ) . However prevalence A/A genotype 18 % Asian Americans Hispanics , thus racial / ethnic group represent ideal model test hypothesis genotype c.935 influence pharmacokinetics pharmacodynamics montelukast . In study , generate preliminary data show AUC montelukast low A/A , intermediate A/G high G/G confirm suitability model replicate earlier finding genotype c.935 associate response montelukast .</detailed_description>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Individuals 735 year old . Individuals healthy doctor diagnose asthma . Individuals 718 year old doctor diagnose asthma . Individuals ( A/A ) genotype c.935 . Individuals must take oral medication except ICS/or albuterol . Women must pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Singulair</keyword>
	<keyword>montelukast</keyword>
	<keyword>Leukotriene Antagonists</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Intestinal Absorption</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>absorption</keyword>
	<keyword>biochemical transport</keyword>
	<keyword>Membrane Transport Proteins</keyword>
</DOC>